Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cellectar Biosciences, Inc. Director's Dealing 2020

Jun 8, 2020

35021_dirs_2020-06-08_9b44996d-6306-4e0d-9e90-06e680548a33.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2020-06-05

Reporting Person: Elefant Dov (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-06-05 Common Stock P 4348 $1.145 Acquired 4348 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-06-05 Series H Warrants $1.2075 P 2174 Acquired 2025-06-05 Common Stock (2174) Direct